Cantor Fitzgerald's Elemer Piros recently upgraded shares of Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) to 'Overweight' alongside a price target of $17.00 per share. With an analyst average price target of $12.83 per share, Piros' price target is the highest out of the analysts we track that cover Zynerba.
With a last trade price of $10.25, this ZYNE price target represents over 65% potential upside. This bullish call is due to assumptions that Zynerba's ZYN002 treatment for Fragile X syndrome will be a commercial success if the drug makes it to market.
“Based on the positive Phase 2 FXS results, we are encouraged by the potential for ZYN002 to treat the disease and have assessed the risk-adjusted opportunity for the drug,” Piros told Benzinga. “With an annual price assumption of $45,000 (U.S.) and $32,000 (EU), ZYN002 could reach combined peak sales of $1.5 billion, in our calculation.” Additionally, "Cantor Fitzgerald estimates Zynerba will finish 2018 with roughly $73 million in cash on its balance sheet."
Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.